Mizuho analyst Uy Ear says that while Biogen’s (BIIB) offer for Sage Therapeutics (SAGE) is a 30% premium to Sage’s Friday’s closing price, which is attractive, the stock has been trading below cash. The offer price implies that the enterprise value for Sage is zero at most, given that Sage could end Q4 with $500M in net cash, the analyst tells investors in a research note. As such, it appears the deal gives no value to Zurzuvae in postpartum depression and no value to any early stage pipeline such as Sage-319, that Sage is excited about, contends Mizuho.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist
- Biogen bid for Sage does not change narrative, says BMO Capital
- BofA moves to No Rating on Sage Therapeutics after Biogen bid
- Morning Movers: Intra-Cellular surges following deal to be bought by J&J
- SAGE Therapeutics Outlines 2025 Strategy and Acquisition Proposal